Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496483 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients
A Phase 2 study, sponsored by Veloxis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00496483 is a Phase 2 study that has completed, run by Veloxis Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00496483, a Phase 2 study, has completed, sponsored by Veloxis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
A three sequence, open-label, multi-center, prospective, study in stable kidney transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.
Interventions
- DRUG Prograf
- DRUG LCP Tacro (tacrolimus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496483
The ClinicalTrials.gov registry entry for NCT00496483 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veloxis Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prograf is the first listed.
NCT00496483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496483 about?
NCT00496483 is a clinical study titled "Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients". A three sequence, open-label, multi-center, prospective, study in stable kidney transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.
What is the current status of trial NCT00496483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2007-07. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00496483?
The interventions under investigation include: Prograf (DRUG), LCP Tacro (tacrolimus) (DRUG).
Who is sponsoring clinical trial NCT00496483?
This trial is sponsored by Veloxis Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.